News | July 26, 2023
Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
AIIMS established in Bilaspur, Nagpur, Rae Bareli and Gorakhpur
Good momentum in commercial CDMO business
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Subscribe To Our Newsletter & Stay Updated
